Kisspeptin

Discovery and Structure

Kisspeptin is a family of peptides encoded by the KISS1 gene, first identified in 1996 at the Hershey Medical Center in Hershey, Pennsylvania, by researchers studying metastasis suppression in melanoma cell lines. The gene was originally named for its discoverers' location — a nod to Hershey's Kisses chocolates — and the product was initially called metastin in reference to its anti-metastatic activity in tumor models. The reproductive-endocrinology role came later, when independent groups in 2003 linked inactivating mutations in GPR54 (now KISS1R) to hypogonadotropic hypogonadism and absent puberty in human families.

The full-length KISS1 translation product is a 145-amino-acid precursor that is cleaved into active fragments — principally kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10. All share a common C-terminal decapeptide that is sufficient for full KISS1R agonist activity, which is why synthetic kisspeptin-10 is the form most used in research.

Mechanism of Action

Kisspeptin acts at KISS1R on hypothalamic GnRH neurons, where it serves as the primary upstream trigger for pulsatile GnRH release. Downstream, this drives pituitary LH and FSH secretion and — at the gonadal level — testosterone production and spermatogenesis in men, follicular development and ovulation in women.

Because kisspeptin sits upstream of the entire HPG axis, it represents the most proximal physiological "switch" that has been identified for reproductive hormone signaling. It is credited as the master regulator that initiates puberty and integrates metabolic, stress, and circadian inputs into the reproductive axis.

Clinical Evidence

Human clinical research on kisspeptin is concentrated in reproductive endocrinology and fertility medicine, with the most productive program led by Waljit Dhillo's group at Imperial College London. Key lines of work include:

• Ovulation trigger in IVF. Kisspeptin-54 has been studied as an alternative to hCG or GnRH agonists for triggering oocyte maturation, with several Phase 2 trials reporting lower rates of ovarian hyperstimulation syndrome.
• Hypothalamic amenorrhea. Pulsatile kisspeptin administration has been shown to restore LH pulsatility in women with functional hypothalamic amenorrhea.
• Hypoactive sexual desire disorder. Small Imperial-led trials have reported enhanced neural and behavioral sexual-arousal responses to kisspeptin infusion in both men and women with low desire.
• Diagnostic use. Kisspeptin challenge testing can distinguish hypothalamic from pituitary causes of hypogonadism.

No kisspeptin product is FDA-approved, and outside specialized research settings it is not available through conventional pharmacy channels.

Practical Considerations

Research dosing typically uses kisspeptin-10 at 50–500 mcg subcutaneously, or kisspeptin-54 by infusion at microgram-per-kg doses in clinical trials. Because the half-life of kisspeptin-10 is short (minutes), community protocols sometimes use frequent dosing — though the translational relevance of infrequent bolus injections to the pulsatile physiology of the native system is limited.

Kisspeptin is mechanistically distinct from gonadorelin (synthetic GnRH): kisspeptin acts upstream of GnRH neurons, while gonadorelin replaces GnRH itself. For users pursuing HPG-axis support without TRT, this upstream-versus-downstream distinction matters — kisspeptin depends on intact GnRH neurons to be effective, while gonadorelin bypasses that step.

Safety and Regulatory Status

In published trials kisspeptin has been well tolerated, with transient flushing, mild nausea, and injection-site reactions the most common adverse events. Because kisspeptin drives endogenous HPG signaling, long-term effects on reproductive and bone health have not been characterized, and fertility-clinic use remains investigational. It is not FDA-approved, not EMA-approved, and available outside academic trials primarily through research-chemical suppliers.

The Bottom Line

Kisspeptin is one of the most mechanistically important discoveries in reproductive endocrinology of the last three decades — the upstream trigger for the entire HPG axis. Its therapeutic development is genuine but early, with the most promising near-term indication being ovulation induction in IVF rather than broad hormonal-support use. Community use as a testosterone-support peptide runs well ahead of the human evidence.